Corbus Pharmaceuticals Holdings (CRBP) Research & Development (2013 - 2025)

Corbus Pharmaceuticals Holdings' Research & Development history runs 13 years deep, the most recent figure standing at $20.9 million for Q3 2025.

• On a quarterly basis, Research & Development rose 93.01% year-over-year to $20.9 million in Q3 2025; TTM through Sep 2025 was $60.5 million, a 98.84% increase from a year earlier, with the FY2024 full-year figure at $32.2 million, up 3.38% from the prior year.
• Research & Development grew to $20.9 million in Q3 2025 per CRBP's latest filing, from $15.2 million in the prior quarter.
• Across five years, Research & Development topped out at $20.9 million in Q3 2025 and bottomed at $380000.0 in Q4 2021.
• The 5-year median for Research & Development is $7.0 million (2023), against an average of $8.5 million.
• Across the five-year window, Research & Development tumbled 97.64% in 2021 and soared 1542.83% in 2022, its largest moves.
• Year by year, Research & Development stood at $380000.0 in 2021, then surged by 1542.83% to $6.2 million in 2022, then increased by 11.81% to $7.0 million in 2023, then advanced by 25.89% to $8.8 million in 2024, then surged by 137.4% to $20.9 million in 2025.
• Per Business Quant, the three latest CRBP Research & Development figures stand at $20.9 million (Q3 2025), $15.2 million (Q2 2025), and $15.6 million (Q1 2025).